{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T07:53:31Z","timestamp":1793951611504,"version":"4.8.0"},"reference-count":184,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T00:00:00Z","timestamp":1721865600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.blre.2024.101222","type":"journal-article","created":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T15:51:07Z","timestamp":1718898667000},"page":"101222","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Immune thrombocytopenia: Pathophysiology and impacts of Romiplostim treatment"],"prefix":"10.1016","volume":"67","author":[{"given":"John W.","family":"Semple","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Schifferli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nichola","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossam","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel T.","family":"Mytych","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynette S.","family":"Chea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Newland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2024.101222_bb0005","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","article-title":"Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group","volume":"113","author":"Rodeghiero","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101222_bb0010","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1182\/blood-2004-12-4598","article-title":"How I treat idiopathic thrombocytopenic purpura (ITP)","volume":"106","author":"Cines","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101222_bb0015","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1046\/j.1365-2141.1996.d01-1872.x","article-title":"Characterization of platelet-reactive antibodies in children with varicella-associated acute immune thrombocytopenic purpura (ITP)","volume":"95","author":"Wright","year":"1996","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2024.101222_bb0020","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1046\/j.1365-2141.2003.04735.x","article-title":"Molecular mimicry by helicobacter pylori CagA protein may be involved in the pathogenesis of H. Pylori-associated chronic idiopathic thrombocytopenic purpura","volume":"124","author":"Takahashi","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2024.101222_bb0025","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1182\/blood-2005-01-0243","article-title":"Role of molecular mimicry to HIV-1 peptides in HIV-1-related immunologic thrombocytopenia","volume":"106","author":"Li","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101222_bb0030","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1053\/j.seminhematol.2008.12.005","article-title":"Pathobiology of secondary immune thrombocytopenia","volume":"46","author":"Cines","year":"2009","journal-title":"Semin Hematol"},{"key":"10.1016\/j.blre.2024.101222_bb0035","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/pbc.21872","article-title":"Demographic data, natural history, and prognostic factors of idiopathic thrombocytopenic purpura in children: a multicentered study from Argentina","volume":"52","author":"Donato","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.blre.2024.101222_bb0040","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1182\/blood-2008-09-181073","article-title":"Role of molecular mimicry of hepatitis C virus protein with platelet GPIIIa in hepatitis C-related immunologic thrombocytopenia","volume":"113","author":"Zhang","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101222_bb0045","first-page":"6","article-title":"Pathogenesis and therapeutic mechanisms in immune thrombocytopenia (ITP)","author":"Zufferey","year":"2017","journal-title":"J Clin Med"},{"key":"10.1016\/j.blre.2024.101222_bb0050","first-page":"10","article-title":"Epidemiology and viral etiology of pediatric immune thrombocytopenia through Korean public health data analysis","author":"Lim","year":"2021","journal-title":"J Clin Med"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2024.101222_bb0055","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1053\/j.seminhematol.2016.04.021","article-title":"Viruses, anti-viral therapy, and viral vaccines in children with immune thrombocytopenia","volume":"53","author":"Elalfy","year":"2016","journal-title":"Semin Hematol"},{"key":"10.1016\/j.blre.2024.101222_bb0060","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1111\/apa.15765","article-title":"Secondary immune thrombocytopenia in children: characteristics and outcome of a large cohort from two Spanish centres","volume":"110","author":"Berrueco","year":"2021","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.blre.2024.101222_bb0065","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0955-3886(98)00039-3","article-title":"Virus-associated idiopathic thrombocytopenic purpura","volume":"19","author":"Rand","year":"1998","journal-title":"Transfus Sci"},{"key":"10.1016\/j.blre.2024.101222_bb0070","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1055\/s-0043-1772771","article-title":"Review: advances in the pathogenesis and treatment of immune thrombocytopenia associated with viral hepatitis","volume":"10","author":"Xu","year":"2023","journal-title":"Glob Med Genet"},{"key":"10.1016\/j.blre.2024.101222_bb0075","doi-asserted-by":"crossref","first-page":"6511","DOI":"10.1182\/blood-2009-01-129155","article-title":"The ITP syndrome: pathogenic and clinical diversity","volume":"113","author":"Cines","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101222_bb0080","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/ajh.26132","article-title":"Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination","volume":"96","author":"Lee","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2024.101222_bb0085","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1182\/blood.V87.10.4245.bloodjournal87104245","article-title":"Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura: relationship to platelet phenotype and antiplatelet T-cell reactivity","volume":"87","author":"Semple","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101222_bb0090","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1182\/blood.V78.10.2619.2619","article-title":"Increased antiplatelet T helper lymphocyte reactivity in patients with autoimmune thrombocytopenia","volume":"78","author":"Semple","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101222_bb0095","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S0002-9343(99)80342-8","article-title":"Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura","volume":"98","author":"Stasi","year":"1995","journal-title":"Am J Med"},{"key":"10.1016\/j.blre.2024.101222_bb0100","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1182\/blood-2009-06-225565","article-title":"International consensus report on the investigation and management of primary immune thrombocytopenia","volume":"115","author":"Provan","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101222_bb0105","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1182\/asheducation-2018.1.405","article-title":"Pediatric ITP: is it different from adult ITP?","volume":"2018","author":"Despotovic","year":"2018","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1335\u20139","key":"10.1016\/j.blre.2024.101222_bb0110","first-page":"e1","article-title":"Age and duration of bleeding symptoms at diagnosis best predict resolution of childhood immune thrombocytopenia at 3, 6, and 12 months","volume":"163","author":"Revel-Vilk","year":"2013","journal-title":"J Pediatr"},{"key":"10.1016\/j.blre.2024.101222_bb0115","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1182\/blood-2014-05-578336","article-title":"Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France","volume":"124","author":"Moulis","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101222_bb0120","first-page":"1041","article-title":"The course of severe autoimmune thrombocytopenia in patients not undergoing splenectomy","volume":"91","author":"Sailer","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2024.101222_bb0125","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/ajh.25086","article-title":"A comparative prospective observational study of children and adults with immune thrombocytopenia: 2-year follow-up","volume":"93","author":"Schifferli","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2024.101222_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.103820","article-title":"Recent advances in the mechanisms and treatment of immune thrombocytopenia","volume":"76","author":"Provan","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.blre.2024.101222_bb0135","doi-asserted-by":"crossref","first-page":"e153580","DOI":"10.1172\/JCI153580","article-title":"High-affinity autoreactive plasma cells disseminate through multiple organs in patients with immune thrombocytopenic purpura","volume":"132","author":"Canales-Herrerias","year":"2022","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2024.101222_bb0140","first-page":"1","article-title":"Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura","volume":"38","author":"Harrington","year":"1951","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.blre.2024.101222_bb0145","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/nm921","article-title":"T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura","volume":"9","author":"Olsson","year":"2003","journal-title":"Nat Med"},{"issue":"924\u201330","key":"10.1016\/j.blre.2024.101222_bb0150","article-title":"The spleen dictates platelet destruction, anti-platelet antibody production, and lymphocyte distribution patterns in a murine model of immune thrombocytopenia","volume":"44","author":"Aslam","year":"2016","journal-title":"Exp Hematol"},{"key":"10.1016\/j.blre.2024.101222_bb0155","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/cei.13475","article-title":"Complement activation in patients with immune thrombocytopenic purpura according to phases of disease course","volume":"201","author":"Castelli","year":"2020","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.blre.2024.101222_bb0160","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1182\/blood-2009-09-244772","article-title":"A murine model of severe immune thrombocytopenia is induced by antibody- and CD8+ T cell-mediated responses that are differentially sensitive to therapy","volume":"115","author":"Chow","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101222_bb0165","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0037-1963(00)90102-1","article-title":"Autoantibodies and autoantigens in chronic immune thrombocytopenic purpura","volume":"37","author":"McMillan","year":"2000","journal-title":"Semin Hematol"},{"key":"10.1016\/j.blre.2024.101222_bb0170","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/ajh.25680","article-title":"Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia","volume":"95","author":"Newland","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2024.101222_bb0175","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood.V59.1.23.23","article-title":"Specificity of autoantibodies in autoimmune thrombocytopenia","volume":"59","author":"van Leeuwen","year":"1982","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101222_bb0180","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1182\/blood.V70.4.1040.1040","article-title":"Platelet-associated and plasma anti-glycoprotein autoantibodies in chronic ITP","volume":"70","author":"McMillan","year":"1987","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101222_bb0185","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/bjh.14664","article-title":"The effect of rituximab on anti-platelet autoantibody levels in patients with immune thrombocytopenia","volume":"178","author":"Arnold","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2024.101222_bb0190","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/bjh.15404","article-title":"Detection of platelet autoantibodies to identify immune thrombocytopenia: state of the art","volume":"182","author":"Porcelijn","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2024.101222_bb0195","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1172\/JCI65689","article-title":"B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells","volume":"123","author":"Mahevas","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2024.101222_bb0200","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1182\/blood-2014-03-563445","article-title":"Splenic TFH expansion participates in B-cell differentiation and antiplatelet-antibody production during immune thrombocytopenia","volume":"124","author":"Audia","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101222_bb0205","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1808217115","article-title":"Akt-mediated platelet apoptosis and its therapeutic implications in immune thrombocytopenia","volume":"115","author":"Chen","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2024.101222_bb0210","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1182\/bloodadvances.2020002003","article-title":"Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia","volume":"4","author":"Robak","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2024.101222_bb0215","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1538-7836.2008.03161.x","article-title":"Splenic macrophages maintain the anti-platelet autoimmune response via uptake of opsonized platelets in patients with immune thrombocytopenic purpura","volume":"7","author":"Kuwana","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2024.101222_bb0220","doi-asserted-by":"crossref","first-page":"250","DOI":"10.3324\/haematol.2020.248385","article-title":"FcgammaRI and FcgammaRIII on splenic macrophages mediate phagocytosis of anti-glycoprotein IIb\/IIIa autoantibody-opsonized platelets in immune thrombocytopenia","volume":"106","author":"Norris","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2024.101222_bb0225","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ajh.25125","article-title":"Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials","volume":"93","author":"Bussel","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2024.101222_bb0230","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/bjh.16959","article-title":"Fostamatinib is an effective second-line therapy in patients with immune thrombocytopenia","volume":"190","author":"Boccia","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2024.101222_bb0235","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1182\/blood.V67.2.421.421","article-title":"Incomplete antigenic cross-reactivity between platelets and megakaryocytes: relevance to ITP","volume":"67","author":"Stahl","year":"1986","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101222_bb0240","doi-asserted-by":"crossref","first-page":"9587","DOI":"10.1016\/S0021-9258(19)38705-8","article-title":"Human platelets and megakaryocytes contain alternately spliced glycoprotein IIb mRNAs","volume":"265","author":"Bray","year":"1990","journal-title":"J Biol Chem"},{"key":"10.1016\/j.blre.2024.101222_bb0245","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1182\/blood-2003-08-2672","article-title":"Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP","volume":"103","author":"McMillan","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101222_bb0250","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1182\/blood-2002-05-1475","article-title":"Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro","volume":"102","author":"Chang","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101222_bb0255","doi-asserted-by":"crossref","first-page":"7737","DOI":"10.1038\/ncomms8737","article-title":"Desialylation is a mechanism of fc-independent platelet clearance and a therapeutic target in immune thrombocytopenia","volume":"6","author":"Li","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2024.101222_bb0260","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1182\/blood-2017-05-784975","article-title":"Fc-independent immune thrombocytopenia via mechanomolecular signaling in platelets","volume":"131","author":"Quach","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101222_bb0265","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3324\/haematol.2019.236117","article-title":"Autoantibody-mediated desialylation impairs human thrombopoiesis and platelet lifespan","volume":"106","author":"Marini","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2024.101222_bb0270","doi-asserted-by":"crossref","first-page":"27445","DOI":"10.1038\/srep27445","article-title":"CD8(+) T cells induce platelet clearance in the liver via platelet desialylation in immune thrombocytopenia","volume":"6","author":"Qiu","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.blre.2024.101222_bb0275","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.3324\/haematol.2021.279751","article-title":"Antiplatelet antibody predicts platelet desialylation and apoptosis in immune thrombocytopenia","volume":"107","author":"Zheng","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2024.101222_bb0280","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bcmd.2016.06.006","article-title":"Differences in frequency and regulation of T follicular helper cells between newly diagnosed and chronic pediatric immune thrombocytopenia","volume":"61","author":"Yao","year":"2016","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.blre.2024.101222_bb0285","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1600-0609.2005.00622.x","article-title":"Cell-mediated lysis of autologous platelets in chronic idiopathic thrombocytopenic purpura","volume":"76","author":"Zhang","year":"2006","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2024.101222_bb0290","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.hemonc.2017.01.001","article-title":"Study of CD4(+), CD8(+), and natural killer cells (CD16(+), CD56(+)) in children with immune thrombocytopenic purpura","volume":"10","author":"El-Rashedi","year":"2017","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"10.1016\/j.blre.2024.101222_bb0295","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1182\/bloodadvances.2017007021","article-title":"Mature murine megakaryocytes present antigen-MHC class I molecules to T cells and transfer them to platelets","volume":"1","author":"Zufferey","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2024.101222_bb0300","first-page":"2417","article-title":"The role of CD8+ T-cell clones in immune thrombocytopenia","volume":"141","author":"Malik","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101222_bb0305","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/bjh.19079","article-title":"The role of T cells and myeloid-derived suppressor cells in refractory immune thrombocytopenia","volume":"203","author":"Yazdanbakhsh","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2024.101222_bb0310","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/bjh.14661","article-title":"Numerical and functional defects in CD8(+) CD28(\u2212) T-suppressor lymphocytes from patients with primary immune thrombocytopenia","volume":"178","author":"Li","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2024.101222_bb0315","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1182\/blood-2015-03-635417","article-title":"CD8+ T cells are predominantly protective and required for effective steroid therapy in murine models of immune thrombocytopenia","volume":"126","author":"Ma","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101222_bb0320","doi-asserted-by":"crossref","first-page":"5021","DOI":"10.1182\/blood-2012-04-424648","article-title":"Splenic proliferative lymphoid nodules distinct from germinal centers are sites of autoantigen stimulation in immune thrombocytopenia","volume":"120","author":"Daridon","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101222_bb0325","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1182\/blood-2007-12-129262","article-title":"Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab","volume":"112","author":"Stasi","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101222_bb0330","doi-asserted-by":"crossref","first-page":"937","DOI":"10.2147\/IJGM.S298888","article-title":"Imbalance of T lymphocyte subsets in adult immune thrombocytopenia","volume":"14","author":"Lin","year":"2021","journal-title":"Int J Gen Med"},{"key":"10.1016\/j.blre.2024.101222_bb0335","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood-2012-02-413526","article-title":"Thymic retention of CD4+CD25+FoxP3+ T regulatory cells is associated with their peripheral deficiency and thrombocytopenia in a murine model of immune thrombocytopenia","volume":"120","author":"Aslam","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101222_bb0340","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1182\/blood-2015-06-655126","article-title":"CD20+ B-cell depletion therapy suppresses murine CD8+ T-cell-mediated immune thrombocytopenia","volume":"127","author":"Guo","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101222_bb0345","doi-asserted-by":"crossref","first-page":"178","DOI":"10.3345\/kjp.2015.58.5.178","article-title":"Association of CD4(+)CD25(+)FoxP3(+) regulatory T cells with natural course of childhood chronic immune thrombocytopenic purpura","volume":"58","author":"Son","year":"2015","journal-title":"Korean J Pediatr"},{"key":"10.1016\/j.blre.2024.101222_bb0350","doi-asserted-by":"crossref","first-page":"4639","DOI":"10.1182\/blood-2010-04-281717","article-title":"Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents","volume":"116","author":"Bao","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101222_bb0355","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000574","article-title":"Immune thrombocytopenia: recent advances in pathogenesis and treatments","volume":"5","author":"Audia","year":"2021","journal-title":"Hemasphere"},{"key":"10.1016\/j.blre.2024.101222_bb0360","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/MOH.0000000000000612","article-title":"An update on the pathophysiology of immune thrombocytopenia","volume":"27","author":"Semple","year":"2020","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.blre.2024.101222_bb0365","series-title":"Platelet Immunology From The Inside Out","first-page":"315","volume":"15","author":"Semple","year":"2020"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2024.101222_bb0370","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1053\/j.seminhematol.2013.03.021","article-title":"Immune thrombocytopenia and B-cell-activating factor\/a proliferation-inducing ligand","volume":"50","author":"Liu","year":"2013","journal-title":"Semin Hematol"},{"key":"10.1016\/j.blre.2024.101222_bb0375","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/MPH.0000000000002414","article-title":"Predictive value of Breg and serum IL-10 concentration levels for acute ITP progression to chronic phase","volume":"44","author":"Aref","year":"2022","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.blre.2024.101222_bb0380","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1182\/blood-2012-05-432575","article-title":"Defective regulatory B-cell compartment in patients with immune thrombocytopenia","volume":"120","author":"Li","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101222_bb0385","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/bjh.19144","article-title":"Systemic immunosuppression depletes peripheral blood regulatory B cells in patients with immune thrombocytopenia","volume":"204","author":"Stimpson","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2024.101222_bb0390","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/bjh.13567","article-title":"Splenic lymphocyte subtypes in immune thrombocytopenia: increased presence of a subtype of B-regulatory cells","volume":"173","author":"Aslam","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2024.101222_bb0395","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1182\/blood-2012-06-434605","article-title":"CD16+ monocytes control T-cell subset development in immune thrombocytopenia","volume":"120","author":"Zhong","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101222_bb0400","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/bjh.16459","article-title":"Platelet and immune characteristics of immune thrombocytopaenia patients non-responsive to therapy reveal severe immune dysregulation","volume":"189","author":"Monzon Manzano","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2024.101222_bb0405","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1111\/jth.13767","article-title":"High-dose dexamethasone or all-trans-retinoic acid restores the balance of macrophages towards M2 in immune thrombocytopenia","volume":"15","author":"Feng","year":"2017","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2024.101222_bb0410","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/ajh.2830370409","article-title":"Suppressed natural killer cell activity in patients with chronic autoimmune thrombocytopenic purpura","volume":"37","author":"Semple","year":"1991","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2024.101222_bb0415","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/bjh.19070","article-title":"Complement in immune thrombocytopenia (ITP): the role of complement in refractory ITP","volume":"203","author":"Weitz","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2024.101222_bb0420","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1080\/25785826.2023.2213976","article-title":"Involvement of the complement system in immune thrombocytopenia: review of the literature","volume":"46","author":"Shindo","year":"2023","journal-title":"Immunol Med"},{"key":"10.1016\/j.blre.2024.101222_bb0425","doi-asserted-by":"crossref","DOI":"10.1080\/09537104.2022.2159019","article-title":"Complement activation negatively affects the platelet response to thrombopoietin receptor agonists in patients with immune thrombocytopenia: a prospective cohort study","volume":"34","author":"Akesson","year":"2023","journal-title":"Platelets"},{"key":"10.1016\/j.blre.2024.101222_bb0430","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/rth2.12388","article-title":"Serum complement levels in immune thrombocytopenia: characterization and relation to clinical features","volume":"4","author":"Cheloff","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.blre.2024.101222_bb0435","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1080\/09537104.2016.1235686","article-title":"Antibodies against complement-regulatory proteins on platelets in immune thrombocytopenia","volume":"28","author":"Unterberger","year":"2017","journal-title":"Platelets"},{"key":"10.1016\/j.blre.2024.101222_bb0440","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1600-0609.2011.01718.x","article-title":"Autoantibody-mediated complement activation on platelets is a common finding in patients with immune thrombocytopenic purpura (ITP)","volume":"88","author":"Najaoui","year":"2012","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2024.101222_bb0445","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/bjh.13648","article-title":"Classical complement pathway activation in immune thrombocytopenia purpura: inhibition by a novel C1s inhibitor","volume":"173","author":"Peerschke","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2024.101222_bb0450","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/j.1365-2141.2009.07995.x","article-title":"Complement activation on platelets correlates with a decrease in circulating immature platelets in patients with immune thrombocytopenic purpura","volume":"148","author":"Peerschke","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2024.101222_bb0455","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1182\/bloodadvances.2021006864","article-title":"Safety and efficacy of classical complement pathway inhibition with sutimlimab in chronic immune thrombocytopenia","volume":"7","author":"Broome","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2024.101222_bb0460","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.cyto.2003.05.001","article-title":"AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl","volume":"25","author":"Broudy","year":"2004","journal-title":"Cytokine"},{"key":"10.1016\/j.blre.2024.101222_bb0465","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0140-6736(08)60203-2","article-title":"Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial","volume":"371","author":"Kuter","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2024.101222_bb0470","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1634\/stemcells.2008-0366","article-title":"Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist","volume":"27","author":"Erickson-Miller","year":"2009","journal-title":"Stem Cells"},{"key":"10.1016\/j.blre.2024.101222_bb0475","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1002625","article-title":"Romiplostim or standard of care in patients with immune thrombocytopenia","volume":"363","author":"Kuter","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2024.101222_bb0480","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1084\/jem.183.2.651","article-title":"Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin","volume":"183","author":"de Sauvage","year":"1996","journal-title":"J Exp Med"},{"key":"10.1016\/j.blre.2024.101222_bb0485","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1055\/s-0039-1678706","article-title":"Platelet apoptosis and PAI-1 are involved in the pro-coagulant state of immune Thrombocytopaenia patients treated with Thrombopoietin receptor agonists","volume":"119","author":"Justo Sanz","year":"2019","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2024.101222_bb0490","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0054723","article-title":"High doses of romiplostim induce proliferation and reduce proplatelet formation by human megakaryocytes","volume":"8","author":"Currao","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.blre.2024.101222_bb0495","doi-asserted-by":"crossref","first-page":"9401","DOI":"10.1038\/s41598-021-88900-6","article-title":"Platelet function and bleeding at different phases of childhood immune thrombocytopenia","volume":"11","author":"Ignatova","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.blre.2024.101222_bb0500","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.jtha.2022.11.039","article-title":"Evaluation of the procoagulant state in chronic immune thrombocytopenia before and after eltrombopag treatment-a prospective cohort study","volume":"21","author":"van Dijk","year":"2023","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2024.101222_bb0505","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/pr.2015.211","article-title":"B-cell hyperfunction in children with immune thrombocytopenic purpura persists after splenectomy","volume":"79","author":"Giordano","year":"2016","journal-title":"Pediatr Res"},{"key":"10.1016\/j.blre.2024.101222_bb0510","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1055\/s-0034-1544001","article-title":"Can immune thrombocytopenia be cured with medical therapy?","volume":"41","author":"Cuker","year":"2015","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.blre.2024.101222_bb0515","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1002\/ajh.26024","article-title":"Early combination treatment of immune thrombocytopenia: is this the way?","volume":"95","author":"Bussel","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2024.101222_bb0520","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1182\/blood-2021-146648","article-title":"Immunomodulation with Romiplostim in young adult primary immune thrombocytopenia (ITP) as second-line strategy (iROM-study)","volume":"138","author":"Schifferli","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101222_bb0525","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/bloodadvances.2019000868","article-title":"A modern reassessment of glycoprotein-specific direct platelet autoantibody testing in immune thrombocytopenia","volume":"4","author":"Al-Samkari","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2024.101222_bb0530","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1182\/blood-2010-09-304931","article-title":"The role of vanin-1 and oxidative stress-related pathways in distinguishing acute and chronic pediatric ITP","volume":"117","author":"Zhang","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101222_bb0535","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00277-013-1855-5","article-title":"Antiplatelet antibodies detected by the MAIPA assay in newly diagnosed immune thrombocytopenia are associated with chronic outcome and higher risk of bleeding","volume":"93","author":"Grimaldi","year":"2014","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2024.101222_bb0540","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3324\/haematol.11582","article-title":"Heterogeneity of terminology and clinical definitions in adult idiopathic thrombocytopenic purpura: a critical appraisal from a systematic review of the literature","volume":"93","author":"Ruggeri","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2024.101222_bb0545","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"Neunert","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2024.101222_bb0550","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","article-title":"Updated international consensus report on the investigation and management of primary immune thrombocytopenia","volume":"3","author":"Provan","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2024.101222_bb0555","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/bjh.12888","article-title":"The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study","volume":"165","author":"Mahevas","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2024.101222_bb0560","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/bjh.13827","article-title":"Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study","volume":"172","author":"Newland","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2024.101222_bb0565","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1182\/blood.2021010735","article-title":"Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia","volume":"138","author":"Palandri","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101222_bb0570","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/pbc.22346","article-title":"Outcome of chronic idiopathic thrombocytopenic purpura in children","volume":"54","author":"Bansal","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.blre.2024.101222_bb0575","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1182\/blood-2021-150257","article-title":"Romiplostim for the treatment of adult patients with newly diagnosed or persistent immune thrombocytopenia: subgroup analysis from a phase 2 study","volume":"138","author":"Newland","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101222_bb0580","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/bjh.15803","article-title":"Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (ITP) for up to 1 year and in those with chronic ITP for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies","volume":"185","author":"Kuter","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2024.101222_bb0585","doi-asserted-by":"crossref","first-page":"16680","DOI":"10.1038\/s41598-019-53209-y","article-title":"Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia","volume":"9","author":"Lozano","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.blre.2024.101222_bb0590","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1182\/blood-2018-99-109791","article-title":"Predictors of remission in adults with immune thrombocytopenia treated with Romiplostim","volume":"132","author":"Newland","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101222_bb0595","doi-asserted-by":"crossref","first-page":"E40","DOI":"10.1002\/ajh.23900","article-title":"Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia","volume":"90","author":"Gonzalez-Lopez","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2024.101222_bb0600","doi-asserted-by":"crossref","first-page":"2135694","DOI":"10.1080\/09537104.2022.2135694","article-title":"Eltrombopag modulates the phenotypic evolution and potential immunomodulatory roles of monocytes\/macrophages in immune thrombocytopenia","volume":"34","author":"Yang","year":"2023","journal-title":"Platelets"},{"key":"10.1016\/j.blre.2024.101222_bb0605","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/bjh.18842","article-title":"Sustained response off treatment in eltrombopag for children with persistent\/chronic primary immune thrombocytopenia: a multicentre observational retrospective study in China","volume":"202","author":"Wang","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2024.101222_bb0610","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/bjh.16327","article-title":"Safety and efficacy of eltrombopag plus pulsed dexamethasone as first-line therapy for immune thrombocytopenia","volume":"189","author":"Zhang","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2024.101222_bb0615","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/ajh.27131","article-title":"Sustained response off-treatment in eltrombopag-treated adult patients with ITP who are refractory or relapsed after first-line steroids: primary, final, and ad-hoc analyses of the phase II TAPER trial","volume":"99","author":"Cooper","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2024.101222_bb0620","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s12185-014-1661-4","article-title":"Induction of immune tolerance to platelet antigen by short-term thrombopoietin treatment in a mouse model of immune thrombocytopenia","volume":"100","author":"Nishimoto","year":"2014","journal-title":"Int J Hematol"},{"key":"10.1016\/j.blre.2024.101222_bb0625","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/09537104.2019.1624709","article-title":"Thrombopoietin receptor agonist (TPO-RA) treatment raises platelet counts and reduces anti-platelet antibody levels in mice with immune thrombocytopenia (ITP)","volume":"31","author":"Kapur","year":"2020","journal-title":"Platelets"},{"key":"10.1016\/j.blre.2024.101222_bb0630","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1182\/blood-2016-01-690727","article-title":"Thrombopoietin receptor agonists shift the balance of Fcgamma receptors toward inhibitory receptor IIb on monocytes in ITP","volume":"128","author":"Liu","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101222_bb0635","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/bjh.18309","article-title":"Thrombopoietin receptor agonists increase splenic regulatory T-cell numbers in immune thrombocytopenia","volume":"198","author":"Pizzi","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2024.101222_bb0640","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1038\/s41423-023-01036-7","article-title":"Intricacies of TGF-beta signaling in Treg and Th17 cell biology","volume":"20","author":"Wang","year":"2023","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.blre.2024.101222_bb0645","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1080\/09537104.2016.1235691","article-title":"Effect of thrombopoietin-receptor agonists on circulating cytokine and chemokine levels in patients with primary immune thrombocytopenia (ITP)","volume":"28","author":"Gudbrandsdottir","year":"2017","journal-title":"Platelets"},{"key":"10.1016\/j.blre.2024.101222_bb0650","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1080\/09537104.2019.1585527","article-title":"Circulating microRNAs in patients with immune thrombocytopenia before and after treatment with thrombopoietin-receptor agonists","volume":"31","author":"Garabet","year":"2020","journal-title":"Platelets"},{"key":"10.1016\/j.blre.2024.101222_bb0655","doi-asserted-by":"crossref","first-page":"5905","DOI":"10.2147\/JIR.S364414","article-title":"The construction of ITP diagnostic modeling based on the expressions of hub genes associated with M1 polarization of macrophages","volume":"15","author":"Wang","year":"2022","journal-title":"J Inflamm Res"},{"key":"10.1016\/j.blre.2024.101222_bb0660","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/09537104.2016.1265925","article-title":"Update on functional and genetic laboratory assays for the detection of platelet microvesicles","volume":"28","author":"Laroche","year":"2017","journal-title":"Platelets"},{"key":"10.1016\/j.blre.2024.101222_bb0665","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3109\/08880011003663390","article-title":"Shams El din El Telbany MA. Platelet microparticles in immune thrombocytopenic purpura in pediatrics","volume":"27","author":"Tantawy","year":"2010","journal-title":"Pediatr Hematol Oncol"},{"key":"10.1016\/j.blre.2024.101222_bb0670","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1182\/bloodadvances.2020001758","article-title":"Platelet-derived extracellular vesicles infiltrate and modify the bone marrow during inflammation","volume":"4","author":"French","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2024.101222_bb0675","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1182\/blood-2015-04-640300","article-title":"Platelet microparticles inhibit IL-17 production by regulatory T cells through P-selectin","volume":"127","author":"Dinkla","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101222_bb0680","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1160\/th14-03-0281","article-title":"Ectosomes released by platelets induce differentiation of CD4+T cells into T regulatory cells","volume":"112","author":"Sadallah","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2024.101222_bb0685","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.3324\/haematol.2018.202283","article-title":"Long-term treatment with romiplostim and treatment-free platelet responses in children with chronic immune thrombocytopenia","volume":"104","author":"Tarantino","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2024.101222_bb0690","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s12185-015-1793-1","article-title":"Sustained remission of chronic immune thrombocytopenia after discontinuation of treatment with thrombopoietin-receptor agonists in adults","volume":"102","author":"Cervinek","year":"2015","journal-title":"Int J Hematol"},{"key":"10.1016\/j.blre.2024.101222_bb0695","doi-asserted-by":"crossref","first-page":"5673","DOI":"10.4081\/hr.2015.5673","article-title":"Feasibility of romiplostim discontinuation in adult thrombopoietin-receptor agonist responsive patients with primary immune thrombocytopenia: an observational retrospective report in real life clinical practice","volume":"7","author":"Carpenedo","year":"2015","journal-title":"Hematol Rep"},{"key":"10.1016\/j.blre.2024.101222_bb0700","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1179\/1607845415Y.0000000041","article-title":"Case study of remission in adults with immune thrombocytopenia following cessation of treatment with the thrombopoietin mimetic romiplostim","volume":"21","author":"Bussel","year":"2016","journal-title":"Hematology"},{"key":"10.1016\/j.blre.2024.101222_bb0705","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/bjh.18692","article-title":"A bibliometric analysis of primary immune thrombocytopenia from 2011 to 2021","volume":"201","author":"Ou","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2024.101222_bb0710","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1182\/bloodadvances.2023009949","article-title":"Deciphering the genetic basis of immune thrombocytopenia: current evidence for genetic predisposition in adult ITP","volume":"7","author":"Georgi","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2024.101222_bb0715","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.3389\/fimmu.2019.01196","article-title":"Immunomodulation in primary immune thrombocytopenia: a possible role of the fc fragment of Romiplostim?","volume":"10","author":"Schifferli","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2024.101222_bb0720","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1182\/blood.V90.5.1821","article-title":"Regulation of the serum concentration of thrombopoietin in thrombocytopenic NF-E2 knockout mice","volume":"90","author":"Shivdasani","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101222_bb0725","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1182\/blood.V93.8.2515","article-title":"Tissue uptake of circulating thrombopoietin is increased in immune-mediated compared with irradiated thrombocytopenic mice","volume":"93","author":"Chang","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101222_bb0730","first-page":"478","article-title":"The physiological response of thrombopoietin (c-Mpl ligand) to thrombocytopenia in the rat","volume":"105","author":"Yang","year":"1999","journal-title":"Br J Haematol"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2024.101222_bb0735","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00277-009-0882-8","article-title":"Animal models of immune thrombocytopenia (ITP)","volume":"89","author":"Semple","year":"2010","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2024.101222_bb0740","doi-asserted-by":"crossref","first-page":"7235639","DOI":"10.1155\/2018\/7235639","article-title":"Icaritin provokes serum Thrombopoietin and downregulates Thrombopoietin\/MPL of the bone marrow in a mouse model of immune thrombocytopenia","volume":"2018","author":"Zhang","year":"2018","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.blre.2024.101222_bb0745","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.intimp.2018.12.032","article-title":"Effect of recombinant human thrombopoietin on immune thrombocytopenia in pregnancy in a murine model","volume":"67","author":"Liu","year":"2019","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.blre.2024.101222_bb0750","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1182\/bloodadvances.2021006438","article-title":"Dissecting platelet proteomics to understand the pathophysiology of immune thrombocytopenia: studies in mouse models","volume":"6","author":"Martinez-Botia","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2024.101222_bb0755","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2023022738","article-title":"Platelet-derived TGF-beta1 induces functional reprogramming of myeloid-derived suppressor cells in immune thrombocytopenia","author":"Wang","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101222_bb0760","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1007\/s11095-011-0420-y","article-title":"Investigation of the pharmacokinetics of romiplostim in rodents with a focus on the clearance mechanism","volume":"28","author":"Wang","year":"2011","journal-title":"Pharm Res"},{"key":"10.1016\/j.blre.2024.101222_bb0765","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s11095-012-0894-2","article-title":"Pharmacokinetic and pharmacodynamic modeling of romiplostim in animals","volume":"30","author":"Krzyzanski","year":"2013","journal-title":"Pharm Res"},{"key":"10.1016\/j.blre.2024.101222_bb0770","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.exphem.2015.02.004","article-title":"Romiplostim promotes platelet recovery in a mouse model of multicycle chemotherapy-induced thrombocytopenia","volume":"43","author":"McElroy","year":"2015","journal-title":"Exp Hematol"},{"issue":"33\u201346","key":"10.1016\/j.blre.2024.101222_bb0775","article-title":"Signaling properties of murine MPL and MPL mutants after stimulation with thrombopoietin and romiplostim","volume":"85","author":"Rommel","year":"2020","journal-title":"Exp Hematol"},{"key":"10.1016\/j.blre.2024.101222_bb0780","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/09553002.2019.1625488","article-title":"Pharmacodynamics of romiplostim alone and in combination with pegfilgrastim on acute radiation-induced thrombocytopenia and neutropenia in non-human primates","volume":"96","author":"Wong","year":"2020","journal-title":"Int J Radiat Biol"},{"key":"10.1016\/j.blre.2024.101222_bb0785","doi-asserted-by":"crossref","first-page":"7155","DOI":"10.1016\/S0021-9258(18)32345-7","article-title":"Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization","volume":"258","author":"Assoian","year":"1983","journal-title":"J Biol Chem"},{"key":"10.1016\/j.blre.2024.101222_bb0790","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1046\/j.0007-1048.2002.03345.x","article-title":"Reduced transforming growth factor-beta1 production by mononuclear cells from patients with active chronic idiopathic thrombocytopenic purpura","volume":"116","author":"Andersson","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2024.101222_bb0795","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2147\/JBM.S309680","article-title":"Effect of cytokine gene polymorphisms on Eltrombopag reactivity in Japanese patients with immune thrombocytopenia","volume":"12","author":"Nomura","year":"2021","journal-title":"J Blood Med"},{"key":"10.1016\/j.blre.2024.101222_bb0800","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.thromres.2012.06.002","article-title":"TGFbeta(1) and sCTLA-4 levels are increased in eltrombopag-exposed patients with ITP","volume":"130","author":"Fujita","year":"2012","journal-title":"Thromb Res"},{"key":"10.1016\/j.blre.2024.101222_bb0805","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/bcp.12370","article-title":"Effect of thrombopoietin-receptor agonists on a proliferation-inducing ligand (APRIL) plasma levels in patients with immune thrombocytopaenia","volume":"78","author":"Alvarez Roman","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.blre.2024.101222_bb0810","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/3676942","article-title":"Aberrant expression of a proliferation-inducing ligand underlies autoimmune mechanisms in immune thrombocytopenia","volume":"2021","author":"Hao","year":"2021","journal-title":"J Immunol Res"},{"key":"10.1016\/j.blre.2024.101222_bb0815","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1007\/s12185-021-03192-w","article-title":"Increasing numbers of CD19 + CD24(high)CD38(high) regulatory B cells and pre-germinal center B cells reflect activated autoimmunity and predict future treatment response in patients with untreated immune thrombocytopenia","volume":"114","author":"Hayashi","year":"2021","journal-title":"Int J Hematol"},{"key":"10.1016\/j.blre.2024.101222_bb0820","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1084\/jem.177.4.1209","article-title":"Soluble CD40 ligand can replace the normal T cell-derived CD40 ligand signal to B cells in T cell-dependent activation","volume":"177","author":"Lane","year":"1993","journal-title":"J Exp Med"},{"key":"10.1016\/j.blre.2024.101222_bb0825","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1182\/blood-2003-07-2367","article-title":"Platelet-associated CD154 in immune thrombocytopenic purpura","volume":"105","author":"Solanilla","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101222_bb0830","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1034\/j.1600-0609.2002.02774.x","article-title":"Significance of chemokines and soluble CD40 ligand in patients with autoimmune thrombocytopenic purpura","volume":"69","author":"Nagahama","year":"2002","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2024.101222_bb0835","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1186\/s12967-016-1064-9","article-title":"Pulsed high-dose dexamethasone modulates Th1-\/Th2-chemokine imbalance in immune thrombocytopenia","volume":"14","author":"Liu","year":"2016","journal-title":"J Transl Med"},{"key":"10.1016\/j.blre.2024.101222_bb0840","article-title":"The role of IL-23\/Th17 pathway in patients with primary immune thrombocytopenia","volume":"10","author":"Ye","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.blre.2024.101222_bb0845","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.3324\/haematol.2011.046417","article-title":"The levels of IL-17A and of the cytokines involved in Th17 cell commitment are increased in patients with chronic immune thrombocytopenia","volume":"96","author":"Rocha","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2024.101222_bb0850","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.clim.2011.05.003","article-title":"Elevated plasma IL-22 levels correlated with Th1 and Th22 cells in patients with immune thrombocytopenia","volume":"141","author":"Cao","year":"2011","journal-title":"Clin Immunol"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2024.101222_bb0855","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1097\/00043426-200312001-00003","article-title":"Pathogenic T-cell responses in patients with autoimmune thrombocytopenic purpura","volume":"25","author":"Semple","year":"2003","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.blre.2024.101222_bb0860","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22147636","article-title":"The role of leptin in childhood immune thrombocytopenia (ITP): an anti-inflammatory agent?","volume":"22","author":"Thomas","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.blre.2024.101222_bb0865","first-page":"194","article-title":"Clinical significance of serum cytokine levels and thrombopoietic markers in childhood idiopathic thrombocytopenic purpura","volume":"10","author":"Del Vecchio","year":"2012","journal-title":"Blood Transfus"},{"key":"10.1016\/j.blre.2024.101222_bb0870","doi-asserted-by":"crossref","first-page":"220","DOI":"10.7150\/ijbs.10178","article-title":"Changes in follicular helper T cells in idiopathic thrombocytopenic purpura patients","volume":"11","author":"Xie","year":"2015","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.blre.2024.101222_bb0875","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22010097","article-title":"Effects of Eltrombopag on in vitro macrophage polarization in pediatric immune thrombocytopenia","volume":"22","author":"Di Paola","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.blre.2024.101222_bb0880","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1182\/bloodadvances.2021006014","article-title":"A single-arm, long-term efficacy and safety study of subcutaneous romiplostim in children with immune thrombocytopenia","volume":"7","author":"Grainger","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2024.101222_bb0885","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/ejh.12807","article-title":"A large observational study of patients with primary immune thrombocytopenia receiving romiplostim in European clinical practice","volume":"98","author":"Steurer","year":"2017","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2024.101222_bb0890","doi-asserted-by":"crossref","first-page":"958","DOI":"10.2298\/VSP210721090V","article-title":"The role of thrombopoietin receptor agonists in the management of adult primary immune thrombocytopenia: a single Centre experience","volume":"79","author":"Virijevi\u0107","year":"2022","journal-title":"Vojnosanit Pregl"},{"key":"10.1016\/j.blre.2024.101222_bb0895","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s12185-020-02893-y","article-title":"Treatment-free remission after thrombopoietin receptor agonist discontinuation in patients with newly diagnosed immune thrombocytopenia: an observational retrospective analysis in real-world clinical practice","volume":"112","author":"Iino","year":"2020","journal-title":"Int J Hematol"},{"key":"10.1016\/j.blre.2024.101222_bb0900","first-page":"227","article-title":"PLATON: use of romiplostim to treat chronic primary immune thrombocytopenia. Memo - Magazine of European","volume":"13","author":"Mihaylov","year":"2020","journal-title":"Med Oncol"},{"key":"10.1016\/j.blre.2024.101222_bb0905","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/ejh.12822","article-title":"TPO-RAs in pITP: description of a case series and analysis of predictive factors for response","volume":"98","author":"Mazzucconi","year":"2017","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2024.101222_bb0910","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1111\/trf.12139","article-title":"Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists","volume":"53","author":"Ghadaki","year":"2013","journal-title":"Transfusion"},{"key":"10.1016\/j.blre.2024.101222_bb0915","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMoa054626","article-title":"AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP","volume":"355","author":"Bussel","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2024.101222_bb0920","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1053\/j.seminhematol.2014.10.007","article-title":"Development of romiplostim: a novel engineered peptibody","volume":"52","author":"Yang","year":"2015","journal-title":"Semin Hematol"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X24000559?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X24000559?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T19:10:49Z","timestamp":1724526649000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X24000559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":184,"alternative-id":["S0268960X24000559"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2024.101222","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune thrombocytopenia: Pathophysiology and impacts of Romiplostim treatment","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2024.101222","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101222"}}